

ALNYLAM PHARMACEUTICALS, INC.

Form 8-K

April 08, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 8, 2016 (April 4, 2016)**

**Alnylam Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-36407**  
**(Commission**

**File Number)**

**77-0602661**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 8-K

**300 Third Street, Cambridge, MA** **02142**  
**(Address of Principal Executive Offices)** **(Zip Code)**  
**Registrant's telephone number, including area code: (617) 551-8200**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Matters.**

On April 4, 2016, pursuant to a Purchase and Sale Agreement (the Agreement ) with 20 Commerce LLC (the Seller ), Alnylam Pharmaceuticals, Inc. (the Company ) completed its previously announced purchase of 12 acres of undeveloped land in Norton, Massachusetts. At the closing, the Company paid the Seller approximately \$8.0 million in cash for the land and related acquisition costs. The Company plans to construct a manufacturing facility at this site for drug substance, including siRNAs and siRNA conjugates, for clinical and commercial use.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALNYLAM PHARMACEUTICALS, INC.

Date: April 8, 2016

By: /s/ Michael P. Mason  
Michael P. Mason

Vice President, Finance and Treasurer